一种来源于乌鸡的抗炎肽及其应用
By accurately identifying and artificially synthesizing the anti-inflammatory peptides LSGPIRFF and SDPWWKAF from the hydrolyzed peptides of black-boned chicken liver, the problems of single anti-inflammatory drug targets and unclear activity of peptide mixtures in the existing technology have been solved, thus achieving effective treatment and quality control for ulcerative colitis.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- SHAANXI SCI TECH UNIV
- Filing Date
- 2025-11-21
- Publication Date
- 2026-07-17
AI Technical Summary
Existing anti-inflammatory drugs for the treatment of ulcerative colitis have problems such as single target, significant side effects and high treatment costs. Furthermore, the active ingredients of the polypeptide mixture extracted from black-boned chicken liver hydrolysate are unclear, making it difficult to achieve standardized application.
Two specific anti-inflammatory peptides, LSGPIRFF and SDPWWKAF, were precisely identified from the hydrolyzed peptides of black-boned chicken liver. These peptides were prepared by artificial solid-phase synthesis and their anti-inflammatory activity was verified in animal experiments. By combining virtual screening strategy to predict their potential targets and intersection targets, their role in ulcerative colitis was verified.
Significantly improves core symptoms of ulcerative colitis, including reducing disease activity index, restoring colon length, improving intestinal histopathological damage, and modulating levels of key pro-inflammatory/anti-inflammatory factors, providing a safe and effective novel therapeutic drug candidate molecule.
Smart Images
Figure CN121159636B_ABST